Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146–62.

PubMed  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020;70(1):7–30.

Google Scholar 

Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):25245–39.

Casiano CA, Mediavilla-Varela M, Tan EM. Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics. 2006;5(10):1745–59.

PubMed  Google Scholar 

Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: Opportunities for Early Cancer Detection. Trends Cancer. 2017;3(3):198–213.

PubMed  Google Scholar 

Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276(23):6880–904.

PubMed  Google Scholar 

Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 2008;222:328–40.

PubMed Central  Google Scholar 

Liu W, Peng B, Lu Y, Xu W, Qian W, Zhang JY. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2011;10(6):331–5.

Google Scholar 

Potluri HK, Ng TL, Newton MA, et al Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. J Immunother Cancer. 2020;8(2):e001510.

Wang H, Zhang B, Li X, et al. Identification and Validation of Novel Serum Autoantibody Biomarkers for Early Detection of Colorectal Cancer and Advanced Adenoma. Front Oncol. 2020;10:1081.

PubMed  PubMed Central  Google Scholar 

Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60(7):1777–88.

Google Scholar 

Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC, Zhang JY. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res. 2008;7(9):4004–12.

PubMed  Google Scholar 

Mustafa MZ, Nguyen VH, Le Naour F, et al. Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma. J Transl Med. 2016;14:17.

PubMed  PubMed Central  Google Scholar 

Dai L, Li J, Tsay JJ, et al. Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer. Oncoimmunology. 2017;6(5):e1310359.

PubMed  PubMed Central  Google Scholar 

Akhtar J, Priya R, Jain V, et al. Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma. BMC Cancer. 2020;20(1):1175.

CAS  PubMed  PubMed Central  Google Scholar 

Dai L, Li J, Xing M, Sanchez TW, Casiano CA, Zhang JY. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer. Prostate. 2016;76(15):1375–86.

PubMed  Google Scholar 

Massa O, Alessio M, Russo L, et al. Serological Proteome Analysis (SERPA) as a tool for the identification of new candidate autoantigens in type 1 diabetes. J Proteomics. 2013;82:263–73.

PubMed  Google Scholar 

Beutgen VM, Perumal N, Pfeiffer N, Grus FH. Autoantibody Biomarker Discovery in Primary Open Angle Glaucoma Using Serological Proteome Analysis (SERPA). Front Immunol. 2019;10:381.

CAS  PubMed  PubMed Central  Google Scholar 

Zhu Q, Liu M, Dai L, et al. Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2013;12(12):1123–8.

PubMed  Google Scholar 

Poletaev A, Pukhalenko A, Kukushkin A, Sviridov P. Detection of Early Cancer: Genetics or Immunology? Serum Autoantibody Profiles as Markers of Malignancy. Anticancer Agents Med Chem. 2015;15(10):1260–3.

PubMed  Google Scholar 

Zaenker P, Gray ES, Ziman MR. Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmun Rev. 2016;15(5):477–83.

Google Scholar 

Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol. 2008;26(31):5060–6.

PubMed  Google Scholar 

Pastorczak A, Domka K, Fidyt K, Poprzeczko M, Firczuk M. Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia. Cancers (Basel). 2021;13(7):1536.

Fulton KM, Ananchenko A, Wolfraim L, Martin S, Twine SM. Classical Immunoproteomics: Serological Proteome Analysis (SERPA) for Antigen Identification. Methods Mol Biol. 2019. 2024: 59-78.

Qin J, Yang Q, Ye H, et al. Using Serological Proteome Analysis to Identify and Evaluate Anti-GRP78 Autoantibody as Biomarker in the Detection of Gastric Cancer. J Oncol. 2020. 2020: 9430737.

Li L, Chen SH, Yu CH, Li YM, Wang SQ. Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res. 2008;7(2):611–20.

PubMed  Google Scholar 

Yoneyama K, Kojima S, Kodani Y, et al. Proteomic identification of autoantibodies in sera from patients with ovarian cancer as possible diagnostic biomarkers. Anticancer Res. 2015;35(2):881–9.

PubMed  Google Scholar 

Qin J, Wang S, Shi J, et al. Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma. Cancer Sci. 2019;110(6):1829–41.

PubMed  PubMed Central  Google Scholar 

Zang R, Li Y, Jin R, et al. Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection. Oncoimmunology. 2019;8(10):e1625689.

PubMed  PubMed Central  Google Scholar 

Vu LP, Prieto C, Amin EM, et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet. 2017;49(6):866–75.

Google Scholar 

Weng X, Zheng S, Shui H, Lin G, Zhou Y. TUFM-knockdown inhibits the migration and proliferation of gastrointestinal stromal tumor cells. Oncol Lett. 2020;20(5):250.

CAS  PubMed  PubMed Central  Google Scholar 

Hamrita B, Nasr HB, Hammann P, Kuhn L, Guillier CL, Chaieb A, Khairi H, Chahed K. An elongation factor-like protein (EF-Tu) elicits a humoral response in infiltrating ductal breast carcinomas: an immunoproteomics investigation. Clin Biochem. 2011;44(13):1097–104.

Google Scholar 

Ye Y, Kuhn C, Kösters M, et al. Anti α-enolase antibody is a novel autoimmune biomarker for unexplained recurrent miscarriages. EBioMedicine. 2019;41:610–22.

PubMed  PubMed Central  Google Scholar 

Lu Y, Qin J, Xiang Y, et al. Experimental evidence for alpha enolase as one potential autoantigen in the pathogenesis of both autoimmune thyroiditis and its related encephalopathy. Int Immunopharmacol. 2020;85:106563.

CAS  PubMed  Google Scholar 

Wei P, Xing Y, Li B, Chen F, Hua H. Proteomics-based analysis indicating α-enolase as a potential biomarker in primary Sjögren’s syndrome. Gland Surg. 2020;9(6):2054–63.

PubMed  PubMed Central  Google Scholar 

Zhan P, Zhao S, Yan H, et al. α-enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer. Mol Carcinog. 2017;56(5):1427–37.

PubMed  Google Scholar 

Li HJ, Ke FY, Lin CC, et al. ENO1 Promotes Lung Cancer Metastasis via HGFR and WNT Signaling-Driven Epithelial-to-Mesenchymal Transition. Cancer Res. 2021;81(15):4094–109.

PubMed  Google Scholar 

Chang GC, Liu KJ, Hsieh CL, et al. Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res. 2006;12(19):5746–54.

PubMed  Google Scholar 

Zhu W, Li H, Yu Y, et al. Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients. Cancer Manag Res. 2018;10:5735–45.

PubMed  PubMed Central  Google Scholar 

Principe M, Borgoni S, Cascione M, et al. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol. 2017;10(1):16.

PubMed  PubMed Central  Google Scholar 

Sun L, Lu T, Tian K, et al. Alpha-enolase promotes gastric cancer cell proliferation and metastasis via regulating AKT signaling pathway. Eur J Pharmacol. 2019;845:8–15.

PubMed  Google Scholar 

Zhang L, Wang H, Dong X. Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer. J Bras Pneumol. 2018;44(1):18–23.

PubMed  PubMed Central  Google Scholar 

Cui JW, Li WH, Wang J, et al. Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics. 2005;4(11):1718–24.

PubMed  Google Scholar 

Zou L, Wu Y, Pei L, et al. Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. Leuk Res. 2005;29(12):1387–91.

PubMed  Google Scholar 

Ueda K, Nakanishi T, Shimizu A, Takubo T, Matsuura N. Identification of L-plastin autoantibody in plasma of patients with non-Hodgkin’s lymphoma using a proteomics-based analysis. Ann Clin Biochem. 2008;45(Pt 1):65–9.

PubMed  Google Scholar 

Ray A, Song Y, Du T, Chauhan D, Anderson KC. Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma. Oncogene. 2020;39(13):2786–96.

PubMed  PubMed Central  Google Scholar 

Shoshan-Barmatz V, Ben-Hail D, Admoni L, Krelin Y, Tripathi SS. The mitochondrial voltage-dependent anion channel 1 in tumor cells. Biochim Biophys Acta. 2015;1848(10 Pt B):2547–75.

PubMed  Google Scholar 

Shteinfer-Kuzmine A, Verma A, Arif T, Aizenberg O, Paul A, Shoshan-Barmaz V. Mitochondria and nucleus cross-talk: Signaling in metabolism, apoptosis, and differentiation, and function in cancer. IUBMB Life. 2021;73(3):492–510.

PubMed  Google Scholar 

Shoshan-Barmatz V, Mizrachi D. VDAC1: from structure to cancer therapy. Front Oncol. 2012;2:164.

PubMed  PubMed Central  Google Scholar 

Arif T, Vasilkovsky L, Refaely Y, Konson A, Shoshan-Barmatz V. Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo. Mol Ther Nucleic Acids. 2014;3(4):e159.

PubMed  PubMed Central  Google Scholar 

Arif T, Krelin Y, Nakdimon I, et al. VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties. Neuro Oncol. 2017;19(7):951–64.

PubMed  PubMed Central  Google Scholar 

Arif T, Paul A, Krelin Y, Shteinfer-Kuzmine A, Shoshan-Barmatz V. Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States. Cancers (Basel). 2018;10(12):499.

Liu X, He B, Xu T, et al. MiR-490-3p Functions As a Tumor Suppressor by Inhibiting Oncogene VDAC1 Expression in Colorectal Cancer. J Cancer. 2018;9(7):1218–30.

PubMed  PubMed Central  Google Scholar 

Arif T, Stern O, Pittala S, Chalifa-Caspi V, Shoshan-Barmatz V. Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept. Cells. 2019;8(11):1330.

Leanza L, Romio M, Becker KA, et al. Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo. Cancer Cell. 2017;31(4):516-531.e10.